Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

The collaboration between Framatome and IBA aims to build a reliable and sustainable network of cutting-edge specialized ...

PET scans use fluorodeoxyglucose (FDG), a radioactive form of glucose, to show how aggressively tumours consume glucose ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...

Ken Herrmann, MD, MBA, from the Universitätsklinikum Essen (Germany), and Johannes Czernin, MD, from the David Geffen School ...

Q2 2025 Earnings Call Transcript January 30, 2025 Cardinal Health, Inc. beats earnings expectations. Reported EPS is $1.93, expectations were $1.74. Operator: Hello, and welcome to the Second Quarter ...

Ariceum Therapeutics GmbH’s radiopharmaceutical 225Ac-SSO110 ([225Ac]satoreotide tetraxetran) has been awarded orphan drug designation by the FDA for the treatment of small-cell lung cancer (SCLC).

Jack Craig took the reins as president and chief executive officer of CNL last April, assuming that role from Joe McBrearty, who had helmed the company for four years prior to that.

The emergence of alpha-emitting radioisotopes, such as Actinium-225, Astatine-211, and Lead-212, may reduce reliance on beta emitters, though supply issues persist. Additionally, alternative beta ...